OTC Naloxone In US: Once Encouraged, Now Stalled
FDA, in unprecedented step, in 2018 published a model DFL for an OTC naloxone nasal spray developed in a study it sponsored, and former FDA Commissioner Scott Gottlieb noted a need for OTC naloxone. Four years later, US remains without OTC naloxone.
You may also be interested in...
In response to highest number of overdose deaths in US history in 2021, 30 members from both chambers of Congress sign letters sent to seven CEOs of naloxone manufacturers.
Communities where opioid overdoses are highest “are less likely to have a physician who can order naloxone for them,” says researcher Nabarun Dasgupta. Naloxone switch developer Michael Hufford says “disconnects” with FDA “continue to hamper and delay OTC naloxone product applications.”
Harm Reduction Therapeutics CEO Michael Hufford says non-profit is “rapidly moving forward” with OTC naloxone NDA.